Read by QxMD icon Read

Cardiovascular Diabetology

Leticia Gomez-Sanchez, Luis Garcia-Ortiz, M Carmen Patino-Alonso, Jose I Recio-Rodriguez, Rigo Fernando, Ruth Marti, Cristina Agudo-Conde, Emiliano Rodriguez-Sanchez, Jose A Maderuelo-Fernandez, Rafel Ramos, Manuel A Gomez-Marcos
BACKGROUND: The cardio-ankle vascular index (CAVI) and brachial-ankle pulse wave velocity (baPWV) can reflect both central and peripheral arterial stiffness. Metabolic syndrome (MetS) and its components may increase arterial stiffness and the risk of cardiovascular diseases. However, the correlation of MetS and its components with arterial stiffness is still not clear. The primary aim of this study is thus the relationship using baPWV and CAVI in Caucasian adults with intermediate cardiovascular risk...
October 24, 2016: Cardiovascular Diabetology
Ferdinando Carlo Sasso, Nadia Lascar, Antonella Ascione, Ornella Carbonara, Luca De Nicola, Roberto Minutolo, Teresa Salvatore, Maria Rosaria Rizzo, Plinio Cirillo, Giuseppe Paolisso, Raffaele Marfella
BACKGROUND: Although numerous studies and metanalysis have shown the beneficial effect of statin therapy in CVD secondary prevention, there is still controversy such the use of statins for primary CVD prevention in patients with DM. The purpose of this study was to evaluate the occurrence of total major adverse cardio-vascular events (MACE) in a cohort of patients with type 2 diabetes complicated by nephropathy treated with statins, in order to verify real life effect of statin on CVD primary prevention...
October 13, 2016: Cardiovascular Diabetology
Wating Su, Yuan Zhang, Qiongxia Zhang, Jinjin Xu, Liying Zhan, Qiqi Zhu, Qingquan Lian, Huimin Liu, Zhong-Yuan Xia, Zhengyuan Xia, Shaoqing Lei
BACKGROUND: Patients with diabetes are prone to develop cardiac hypertrophy and more susceptible to myocardial ischemia-reperfusion (I/R) injury, which are concomitant with hyperglycemia-induced oxidative stress and impaired endothelial nitric oxide (NO) synthase (eNOS)/NO signaling. Caveolae are critical in the transduction of eNOS/NO signaling in cardiovascular system. Caveolin (Cav)-3, the cardiomyocytes-specific caveolae structural protein, is decreased in the diabetic heart in which production of reactive oxygen species are increased...
October 12, 2016: Cardiovascular Diabetology
Shuhei Takahashi, Kazunori Shimada, Katsumi Miyauchi, Tetsuro Miyazaki, Eiryu Sai, Manabu Ogita, Shuta Tsuboi, Hiroshi Tamura, Shinya Okazaki, Tomoyuki Shiozawa, Shohei Ouchi, Tatsuro Aikawa, Tomoyasu Kadoguchi, Hamad Al Shahi, Takuma Yoshihara, Makoto Hiki, Kikuo Isoda, Hiroyuki Daida
BACKGROUND: Postprandial hyperglycemia plays an important role in the pathogenesis of coronary artery disease and cardiovascular events. Serum 1,5-anhydroglucitol (1,5-AG) levels are known to be a clinical marker of postprandial hyperglycemia. However, the impact of 1,5-AG level on cardiovascular events has not been fully investigated. METHODS: We enrolled 240 consecutive patients who had undergone first-time elective percutaneous coronary intervention (PCI) with follow-up angiography within 1 year...
October 11, 2016: Cardiovascular Diabetology
Mark W Kennedy, Enrico Fabris, Alexander J Ijsselmuiden, Holger Nef, Sebastian Reith, Javier Escaned, Fernando Alfonso, Niels van Royen, Wojtek Wojakowski, Adam Witkowski, Ciro Indolfi, Jan Paul Ottervanger, Harry Suryapranata, Elvin Kedhi
BACKGROUND: Fractional flow reserve (FFR) is a widely used tool for the identification of ischaemia-generating stenoses and to guide decisions on coronary revascularisation. However, the safety of FFR-based decisions in high-risk subsets, such as patients with Diabetes Mellitus (DM) or vulnerable stenoses presenting thin-cap fibro-atheroma (TCFA), is unknown. This study will examine the impact of optical coherence tomography (OCT) plaque morphological assessment and the identification of TCFA, in combination with FFR to better predict clinical outcomes in DM patients...
October 10, 2016: Cardiovascular Diabetology
Junling Fu, Cong Hou, Lujiao Li, Dan Feng, Ge Li, Mingyao Li, Changhong Li, Shan Gao, Ming Li
BACKGROUND: Betatrophin has been recently reported to play a role in glucose homeostasis by inducing beta-cell proliferation in mice. However, studies in human are inconsistent. As a nutritionally-regulated liver-enriched factor, we hypothesize that betatrophin might be regulated by vitamin D, and ignorance of vitamin D status may explain the discrepancy in previous human studies. The aims of this study were to assess the association between circulating betatrophin and glucose homeostasis as well as other cardiometabolic variables in a cohort of youths at risk for metabolic syndrome and test the possible influence of vitamin D status on the association...
October 6, 2016: Cardiovascular Diabetology
S A Paul Chubb, Wendy A Davis, Kirsten E Peters, Timothy M E Davis
BACKGROUND: Serum bicarbonate is associated with mortality, heart failure (HF) and progression of renal failure in studies of healthy people and patients with chronic kidney disease, but the significance of these observations in unselected patients with diabetes in the general population is unknown. The aim of this study was to determine whether serum bicarbonate was associated with mortality and cardiovascular disease risk in type 2 diabetes. METHODS: Baseline serum bicarbonate was available for 1283 well-characterized community-based patients (mean ± SD age 64...
October 6, 2016: Cardiovascular Diabetology
Katherine E Beaney, Claire E Ward, Dauda A S Bappa, Nadine McGale, Anna K Davies, Shashivadan P Hirani, KaWah Li, Philip Howard, Dwaine R Vance, Martin A Crockard, John V Lamont, Stanton Newman, Steve E Humphries
BACKGROUND: The coronary risk in diabetes (CoRDia) trial (n = 211) compares the effectiveness of usual diabetes care with a self-management intervention (SMI), with and without personalised risk information (including genetics), on clinical and behavioural outcomes. Here we present an assessment of randomisation, the cardiac risk genotyping assay, and the genetic characteristics of the recruits. METHODS: Ten-year coronary heart disease (CHD) risk was calculated using the UKPDS score...
October 3, 2016: Cardiovascular Diabetology
Junfeng Li, Nan Wu, Wenling Dai, Liu Jiang, Yintao Li, Shibao Li, Zhongyuan Wen
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a recognized trigger factor for heart failure with preserved ejection fraction (HFpEF). Recent studies show that higher serum calcium level is associated with greater risk of both T2DM and heart failure. We speculate that increased serum calcium is related to HFpEF prevalence in patients with T2DM. METHODS: In this cross-sectional echocardiographic study, 807 normocalcemia and normophosphatemia patients with T2DM participated, of whom 106 had HFpEF...
October 3, 2016: Cardiovascular Diabetology
Oliver Schnell, Lars Rydén, Eberhard Standl, Antonio Ceriello
Cardiovascular disease (CVD) is one of the most common diabetes-associated complications, as well as a leading cause for death in type 2 diabetes patients (T2D). Despite the well-known correlation between the two, up until the 2008 FDA industry guidance for licensing of new anti-hyperglycemic drugs, which required an investigation of cardiovascular outcomes (CVO) of glucose-lowering agents, only a few studies had looked into the relationship between glucose lowering drugs and cardiovascular (CV) risk. Thereafter, CVOT design has focused on non-inferiority short-term studies on high-risk patient populations aiming at capturing CV safety issues...
October 1, 2016: Cardiovascular Diabetology
Katharina S Weber, Birgit Knebel, Klaus Strassburger, Jörg Kotzka, Peter Stehle, Julia Szendroedi, Karsten Müssig, Anette E Buyken, Michael Roden
AIMS: In patients with type 2 diabetes (T2D), responsiveness of serum lipid concentrations to dietary patterns may vary by genotype. The aims of the present study were to identify explorative dietary patterns and to examine their independent associations with serum lipid levels and interactions with apolipoprotein (Apo)A5 and ApoE variants among patients recently diagnosed with T2D. METHODS: Within a cross-sectional analysis, participants of the German Diabetes Study (n = 348) with mean T2D duration of 6 months were investigated for fasting serum lipid levels, ApoA5 and ApoE genotypes; food consumption frequencies were assessed by a food propensity questionnaire...
September 27, 2016: Cardiovascular Diabetology
Yu Mi Kang, Ye-Jee Kim, Joong-Yeol Park, Woo Je Lee, Chang Hee Jung
BACKGROUND: We aimed to investigate the mortality rate (MR), causes of death and standardized mortality ratio (SMR) in Korean type 2 diabetic patients from 2002 to 2013 using data from the Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC). METHODS: From this NHIS-NSC, we identified 29,807 type 2 diabetic subjects from 2002 to 2004. Type 2 diabetes was defined as a current medication history of anti-diabetic drugs and the presence of International Classification of Diseases (ICD)-10 codes (E11-E14) as diagnosis...
September 13, 2016: Cardiovascular Diabetology
Yu Du, Qingwei Ji, Lun Cai, Fangjiong Huang, Yongqiang Lai, Yue Liu, Jianbo Yu, Bo Han, Enjun Zhu, Jinwei Zhang, Yujie Zhou, Zhijian Wang, Yingxin Zhao
BACKGROUND: Omentin-1, a novel adipocytokine mainly expressed in visceral adipose tissue, has been found to inhibit the inflammatory response and improve insulin resistance as well as other obesity-related disorders. This study investigated the association between omentin-1 expression in human epicardial adipose tissue (EAT) and coronary atherosclerosis. METHODS: Serum samples, and paired biopsies from EAT and subcutaneous adipose tissue (SAT), were obtained from patients with and without coronary artery disease (CAD, n = 28 and NCAD, n = 12, respectively) during elective cardiac surgery...
June 28, 2016: Cardiovascular Diabetology
Thijs T W van Herpt, Abbas Dehghan, Mandy van Hoek, M Arfan Ikram, Albert Hofman, Eric J G Sijbrands, Oscar H Franco
BACKGROUND: To evaluate the clinical value of metabolic syndrome based on different definitions [American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI), International Diabetes Federation (IDF) and European Group for the Study of Insulin Resistance (EGIR)] in middle-aged and elderly populations. METHODS: We studied 8643 participants from the Rotterdam study (1990-2012; mean age 62.7; 57.6 % female), a large prospective population-based study with predominantly elderly participants...
April 27, 2016: Cardiovascular Diabetology
Takashi Nakamura, Yoshitaka Iwanaga, Yuki Miyaji, Ryuji Nohara, Takao Ishimura, Shunichi Miyazaki
BACKGROUND: Gliptins should have beneficial effects beyond glycemic control, potentially on the pathophysiology of cardiovascular (CV) diseases, with some basic studies demonstrating this possibility. However, we are yet to answer whether there are any direct CV effects in the clinical setting. We aimed to examine the beneficial effects of sitagliptin in Japanese patients with diabetes and high CV risk for 12 months. METHODS: This was a prospective, multicenter, observational study of 205 patients with type 2 diabetes...
March 31, 2016: Cardiovascular Diabetology
Christian Sonesson, Peter A Johansson, Eva Johnsson, Ingrid Gause-Nilsson
BACKGROUND: A pre-specified meta-analysis of cardiovascular (CV) events from 21 phase 2b/3 dapagliflozin clinical trials was undertaken to characterise the CV profile of dapagliflozin. This showed no increase in CV risk with dapagliflozin compared with control (placebo or comparator treatment) with or without background glucose-lowering therapies. The analysis reported here aimed to characterise the CV profile of dapagliflozin in subgroups of patients in these 21 studies grouped by degree of CV risk, based on both baseline and in-study risk factors (including hypoglycaemic events), with a focus on major adverse CV events (MACE)...
February 19, 2016: Cardiovascular Diabetology
L Masmiquel, L A Leiter, J Vidal, S Bain, J Petrie, E Franek, I Raz, A Comlekci, S Jacob, L van Gaal, F M M Baeres, S P Marso, M Eriksson
BACKGROUND: Epidemiological data on obesity are needed, particularly in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular (CV) risk. We used the baseline data of liraglutide effect and action in diabetes: evaluation of CV outcome results-A long term Evaluation (LEADER) (a clinical trial to assess the CV safety of liraglutide) to investigate: (i) prevalence of overweight and obesity; (ii) relationship of the major cardiometabolic risk factors with anthropometric measures of adiposity [body mass index (BMI) and waist circumference (WC)]; and (iii) cardiometabolic treatment intensity in relation to BMI and WC...
February 10, 2016: Cardiovascular Diabetology
Carlos Henrique Reis Esselin Rassi, Timothy W Churchill, Carlos A Fernandes Tavares, Mateus Guimaraes Fahel, Fabricia P O Rassi, Augusto H Uchida, Bernardo L Wajchenberg, Antonio C Lerario, Edward Hulten, Khurram Nasir, Márcio S Bittencourt, Carlos Eduardo Rochitte, Ron Blankstein
BACKGROUND: There is increasing evidence to suggest that not all individuals with type 2 diabetes mellitus (T2DM) have equal risk for developing cardiovascular disease. We sought to compare the yield of testing for pre-clinical atherosclerosis with various approaches. METHODS: 98 asymptomatic individuals with T2DM without known coronary artery disease (CAD) were enrolled in a prospective study and underwent carotid ultrasound, exercise treadmill testing (ETT), coronary artery calcium (CAC) scoring, and coronary computed tomography angiography (CTA)...
February 9, 2016: Cardiovascular Diabetology
Yaron Arbel, Robert Klempfner, Aharon Erez, Ilan Goldenberg, Sagit Benzekry, Nir Shlomo, Enrique Z Fisman, Alexander Tenenbaum
BACKGROUND: Recent data support the renewed interest in hypertriglyceridemia as a possible important therapeutic target for cardiovascular risk reduction. This study was designed to address the question of all-cause mortality during extended follow-up of the BIP trial in patients stratified by baseline triglyceride levels. METHODS: In the BIP trial 3090 patients with proven coronary artery disease were randomized to bezafibrate 400 mg/day or placebo. All-cause mortality data after 20 years of follow-up, were obtained from the National Israeli Population Registry...
January 22, 2016: Cardiovascular Diabetology
Peter Godsk Jørgensen, Magnus Thorsten Jensen, Tor Biering-Sørensen, Rasmus Mogelvang, Søren Galatius, Thomas Fritz-Hansen, Peter Rossing, Tina Vilsbøll, Jan Skov Jensen
BACKGROUND: Recently, genetic studies have suggested a causal relationship between cholesterol remnants and ischemic heart disease. We aimed to determine whether cholesterol remnants and its marker, triglyceride levels, are associated with cardiac function as determined by sensitive echocardiographic measures in a population of patients with type 2 diabetes. METHODS: Comprehensive echocardiography including 2D-speckle tracking echocardiography was performed on a representative sample of 924 patients with type 2 diabetes-730 of whom were treated with statins...
2016: Cardiovascular Diabetology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"